Eli Lilly’s investigational treatment tirzepatide has actually shown exceptional A1C and body weight decrease compared to injectable semaglutide in grownups with type 2 diabetes.
The SURPASS-2 medical trial compared 3 dosages of tirzepatide– 5mg, 10mg and 15mg– to those taking injectable semaglutide 1mg– marketed by Novo Nordisk as Ozempic.
Topline arise from the trial discovered that the greatest dosage of tirzepatide (15mg) lowered A1C by 2.46% and body weight by 13.1%.
The most affordable does of tirzepatide (5mg) lowered A1C by 2.09% and body weight by 8.5% compared to 1.86% and 6.7% for semaglutide.
In addition, 51% of clients getting tirzepatide 15mg accomplished an A1C of less than 5.7% – the level seen in individuals without diabetes– compared to 20% for those getting semaglutide treatment.
” These striking head-to-head outcomes exceeded our expectations, supporting our belief in the worth of all 3 dosages of tirzepatide as possible brand-new treatment alternatives for individuals coping with type 2 diabetes,” stated Mike Mason, president, Lilly Diabetes.
.